Grafico Azioni Glaxosmithkline (LSE:GSK)
6 Mesi : Da Ago 2019 a Feb 2020
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) upgraded its guidance on Wednesday after it posted growing profit in the third quarter on revenue that beat market expectations.
The British pharmaceutical company made a pretax profit of 1.95 billion pounds ($2.51 billion) in the third quarter, compared with GBP1.71 billion the year earlier. Turnover increased 16% to GBP9.39 billion, beating analyst forecasts of GBP9.04 billion.
Meanwhile adjusted earnings per share--a metric closely watched by analysts--rose to 38.6 pence from 35.5 pence in the third quarter of 2019.
Glaxo said that it is now sees full-year adjusted EPS flat when accounting for currency effects. Previously, the company guided for a decrease of between 3% to 5%.
It confirmed that it was on track to file a new drug application for its cancer drug Zejula by the end of the year having reported positive data from a clinical trial in September that looked at the medicine as a treatment for ovarian cancer.
The company declared a quarterly dividend of 19 pence a share and confirmed its 80 pence total target for the full-year.
Write to Carlo Martuscelli at email@example.com; @carlomartu
(END) Dow Jones Newswires
October 30, 2019 08:37 ET (12:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.